Jazz Pharmaceuticals plc
JAZZHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Jazz Pharmaceuticals plc focuses on Biotechnology services and products. Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. With a market capitalization of $16.07B, it sits in large-cap territory. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Market Cap
$16.07B
Beta
0.36
P/E (TTM)
16.96
P/E (Fwd)
9.61
EPS (TTM)
$14.60
EPS (Fwd)
$25.77
ROE
22.1%
ROA
6.9%
Cash
$2.20B
Total Debt
$4.41B
Free CF
$1.43B
52W Change
89.6%
Annual Financials
Cash vs Debt
Where JAZZ stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, JAZZ finished 13.83% above its 150-day moving average ($214.83) and 20.48% above its 200-day moving average ($202.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JAZZ overbought or oversold?
At the August 31, 2026 close, JAZZ's RSI(14) was 39.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Jazz Pharmaceuticals plc carries $4.41B in total debt against $2.20B in cash reserves — debt is roughly 2.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $1.43B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 22.1% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $3.66B to $4.27B.
With a beta below 0.7, Jazz Pharmaceuticals plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Jazz Pharmaceuticals plc and its sector.